盐酸缬更昔洛韦片治疗效果怎样呢？

It is an oral anti-cytomegalovirus infection drug that combines the advantages of oral administration and intravenous injection. It can effectively prevent and treat cytomegalovirus infection through correct oral administration every day, and significantly improve the patient's quality of life and long-term survival rate.

Clinical studies of valganciclovir hydrochloride tablets in AIDS patients infected with CMV retinitis have shown that valganciclovir hydrochloride tablets and intravenous ganciclovir are equally effective in the induction treatment of CMV retinitis. In the study, patients with newly diagnosed CMV retinitis were randomly assigned to the valganciclovir hydrochloride tablet group or the intravenous ganciclovir group for induction therapy. The proportion of patients with progression of CMV retinitis at week 4 was the same in both groups. After induction therapy, both groups of patients in the study continued to receive maintenance therapy with valganciclovir hydrochloride tablets 900 mg per day. Among patients who received induction therapy with valganciclovir hydrochloride tablets or intravenous ganciclovir tablets followed by maintenance therapy with valganciclovir hydrochloride tablets, the mean (median) time from randomization to progression of CMV retinitis was: 226 (160) days and 219 (125) days.

The recommended dose of valganciclovir hydrochloride tablets for the treatment of induction of cytomegalovirus retinitis is 900 mg (two 450 mg tablets) twice daily for 21 days. Maintenance: After induction therapy, or in adult patients with inactive cytomegalovirus retinitis, the recommended dose is 900 mg orally once daily.

Cytomegalovirus prophylaxis: For adult patients who have received a heart or kidney-pancreas transplant, the recommended dose is 900 mg orally once daily starting within 10 days of transplantation and continuing until 100 days after transplantation.

Clinical antiviral effects were demonstrated in the treatment of AIDS patients with newly diagnosed retinitis (clinical study WV15376). After 4 weeks of treatment with valganciclovir hydrochloride tablets, the detection rate of CMV virus decreased from 46% (32/69) to 7% (4/55).